Edition:
United Kingdom

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.82USD
5:07pm GMT
Change (% chg)

$-0.01 (-0.62%)
Prev Close
$0.82
Open
$0.85
Day's High
$0.85
Day's Low
$0.82
Volume
21,736
Avg. Vol
180,268
52-wk High
$5.25
52-wk Low
$0.78

Chart for

About

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $19.05
Shares Outstanding(Mil.): 21.55
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 8.52 16.44
EPS (TTM): -- -- --
ROI: -- 16.37 10.62
ROE: -- 19.48 14.20

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage:

16 Nov 2017

BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO

* Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer

07 Nov 2017

BRIEF-DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6

* DelMar Pharmaceuticals Inc CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing Source text: (http://bit.ly/2kDnPBr) Further company coverage:

10 Oct 2017

BRIEF-DelMar Pharmaceuticals announces $10 million registered direct offering

* Announces $10 million registered direct offering priced at-the-market

20 Sep 2017

BRIEF-Delmar Pharmaceuticals receives IND allowance from FDA

* Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer Source text for Eikon: Further company coverage:

18 Sep 2017

BRIEF-Delmar Pharmaceuticals initiates phase 2 clinical trial

* Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme

11 Sep 2017

BRIEF-Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083

* Delmar Pharmaceuticals receives approval from China's Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM

24 Jul 2017

BRIEF-Delmar Pharmaceuticals reports completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory GBM

* Delmar Pharmaceuticals announces completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory gbm

18 Jul 2017

BRIEF-Delmar Pharmaceuticals appoints Saiid Zarrabian to board

* Delmar Pharmaceuticals appoints Saiid Zarrabian to the board of directors and names Erich Mohr as chairman

11 Jul 2017

BRIEF-DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM

* DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM

22 Jun 2017

Competitors

Earnings vs. Estimates